US › Healthcare

Fulgent Genetics Inc (FLGT)

US · Healthcare · Diagnostics & Research

$18.55+5.34%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$85.4M
Revenue YoY
+4.4%
Net profit
$-29.5M
Profit YoY
-55.8%
EPS
$-0.88
EPS estimate
$-0.79
Net margin
-34.6%

EPS came in at -0.88 against a street estimate of -0.79 — a miss of 11.4%.

Key statistics

Market cap
$470.0M
Forward P/E
7.7
P/B
0.47
Book value
$36.40
EPS (TTM)
$-2.83
52-week high
$31.04
52-week low
$13.46
50-day MA
$19.21
200-day MA
$21.36
Beta
0.91

Analyst view

Analysts rate Fulgent Genetics Inc a hold (1 buy, 2 hold, 0 sell out of 3) with an average price target of $15.00.

Shareholding

Insiders
37.81%
Institutions
65.70%

Largest institutional holders

FundStake
BlackRock Inc10.08%
RTW INVESTMENTS, LLC4.68%
Acadian Asset Management LLC4.48%
Vanguard Capital Management, LLC3.20%
Dimensional Fund Advisors, Inc.2.44%
Invenomic Capital Management, LP2.22%
Geode Capital Management, LLC2.12%
Ameriprise Financial Inc2.05%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Fulgent Genetics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.